800+ advanced ovarian cancer patients enrolled in the phase III trial of the PARP-1 inhibitor Veliparib (VELIA)….Pairwise analysis of individual features with clinical outcomes shows that increased tumor-mutation burden (TMB)...were each significantly associated with longer PFS and less progressive disease (PD). Similarly, homologous recombination deficiency (HRD) and BRCA alteration were associated with better clinical outcomes, while high CA-125 was associated with worse outcomes.

NON-SUPPORTIVE EVIDENCE: A total of 532 patients from veliparib-throughout and control arms with HGSC confirmed BRCAwt and known HRD status were included in this exploratory analysis to evaluate HRD independent of BRCA status. This analysis of BRCAwt HRD+ and non-HRD populations suggests veliparib benefit is similar in both groups.

...analyzed sequentially in the BRCA-mutation cohort, the cohort with homologous-recombination deficiency (HRD) (which included the BRCA-mutation cohort), and the intention-to-treat population....in the HRD cohort, it was 31.9 months and 20.5 months, respectively (hazard ratio, 0.57; 95 CI, 0.43 to 0.76; P<0.001); and in the intention-to-treat population, it was 23.5 months and 17.3 months (hazard ratio, 0.68; 95% CI, 0.56 to 0.83; P<0.001).

...Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort`PFS was defined as the time from the date that the participant was randomized to the date the participant experienced an event of disease progression, according to Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1 (as determined by the investigator) or to the date of death (all causes of mortality) if disease progression was not reached. ...